Alnylam Pharmaceuticals
NEWS
Alnylam Pharmaceuticals’ lumasiran for a chronic kidney stone disease was granted Priority Review status by the U.S. Food and Drug Administration. It will have a target action date of December 3, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 4, 2020.
“Blackstone is uniquely positioned to provide customized, one-stop-shop financing solutions at scale while establishing development collaborations with the world’s leading biotech companies,” said Nicholas Galakatos, global head of Blackstone Life Sciences.
At least three different biotech companies are working on two ACE2-related drugs to find a solution to the COVID-19 pandemic.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 10, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 2, 2020.
As the coronavirus outbreak that causes COVID-19 escalates, biopharma companies and government agents are working quickly to develop and test a vaccine, although most estimates are it will take 12 to 18 months before it could get to market.
Brandicourt stepped down from his role as chief executive officer of Sanofi last year.
Although January was a fairly slow month for PDUFA dates for the U.S. Food and Drug Administration, February has a stronger schedule.
JOBS
IN THE PRESS